Trial Profile

A Retrospective Cohort Study to Compare Hospitalizations among Adult Patients with Schizophrenia Newly Treated with Brexpiprazole Versus Other US FDA-Approved Oral Atypical Antipsychotics (OAAs) in a Real-World Setting

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brexpiprazole (Primary) ; Aripiprazole; Lurasidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
Indications Schizophrenia
Focus Therapeutic Use

10 Jan 2020 Results comparing all cause and psychiatric inpatient hospitalization and medical costs in adult patients with schizophrenia were published in the Clinical Therapeutics
22 May 2019 Results presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
22 May 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com